Total Synthetic Development and Pharmacological Screening of Bioactive Isolated from Syzygium cuminii (l) Skeel

Abstract

Syzygium cumini (L.) Skeels (or Eugenia jambolana) is a species that belongs to the Myrtaceae family been used empirically to treat various diseases, one of them is antidiabetic. The study reported the phytochemical analysis and pharmacological screening of In-vivo, antidiabetic test conducted on bioactive (separated by column isolation method from aqueous extract) in streptozotocine induced diabetes rat modelling at dose level of 50 g/kg BW, on the basis of TLC and spectral analysis of activity guided bioactive will be chemically designate as 4-(2-amino-2 -(2-(2-hydroxy-3-methyl butyl) octahydropyrrolo-[1,2-a] pyrazin-7-yl)-ethyl)-2- ethylpheno (ScReX-2), Total synthetic methodology accomplished using key BoC protected, pyrazine and methyl amine followed by condensation with application of simple Diels-alder reaction of fragment by cyclization. The Structure elucidation of the newly synthesized ScReX-2 was performed by means of FT-IR, 1H-NMR, 13C-NMR, the antidiabetic activity showed that the effect of synthesized molecule at dose level of 50mg/kg BW was exhibits more potent significantly then glibenclamide to reduce the blood glucose levels subset of the statistics ANOVA (p> 0.05). The study concludes that the synthesized bioactive is having potent antidiabetic activity then compared with isolated molecule as well as glibenclamide.